Dr. Schwartzberg has disclosed that he receives consulting fees and/or honoraria from Amgen Inc., Genentech, Inc., and TESARO, Inc.; is a scientific advisor for Bristol-Myers Squibb Company, Caris Life Sciences, and Helsinn; and is on the product/speakers bureau for Genentech, Inc. and Pfizer Inc. Dr. Blair has disclosed that she has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007;25:1683–1690.
Weiss A, Noorbakhsh A, Tokin C et al.. Hormone receptor-negative breast cancer: undertreatment of patients over 80. Ann Surg Oncol 2013;20:3274–3278.
Kimick GG, Muss HB. Breast disease. In: Halter JB, Ouslander JG, Tinetti ME et al., eds. Hazzard's Geriatric Medicine and Gerontology. Columbus, OH: McGraw Hill; 2009.
Joerger M, Thurlimann B, Savidan A et al.. Treatment of breast cancer in the elderly: a prospective population-based Swiss Study. J Geriatr Oncol 2013;4:39–47.
Angarita FA, Chesney T, Elser C et al.. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres. Eur J Surg Oncol 2015;41:625–634.
Hamaker ME, Bastiaannet E, Evers D et al.. Omission of surgery in elderly patients with early stage breast cancer. Eur J Cancer 2013;49:545–552.
Cortadellas T, Gascón A, Córdoba O et al.. Surgery improves breast cancer-specific survival in octogenarians with early-stage breast cancer. Int J Surg 2013;11:554–557.
Yood MU, Owusu C, Buist DS et al.. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 2008;206:66–75.
Hughes KS, Schnaper LA, Bellon JR et al.. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382–2387.
Dinan MA, Mi X, Reed SD et al.. Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005–2009. JAMA Oncol 2015;1:158–166.
Shak S, Petkov VI, Miller DP et al.. Breast cancer specific survival in 38,568 patients with node-negative hormone receptor-positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database [abstract]. Cancer Res 2016;76(4 Suppl):Abstract P5-15-01.
- Search Google Scholar
- Export Citation
. Shak S Petkov VI Miller DP Breast cancer specific survival in 38,568 patients with node-negative hormone receptor-positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database [abstract]. Cancer Res 2016; 76( 4 Suppl): Abstract P5-15-01.
Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet 2015;386:1341–1352.
Huss HB, Tu D, Ingle JN et al.. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008;26:1956–1964.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Coleman R, Powles T et al.. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials. Lancet 2015;386:1353–1361.
Tolaney SM, Barry WT, Dang CT et al.. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015;372:134–141.